Nuvilex (NASDAQ:PMCB) CEO Purchases $33,200.00 in Stock

Nuvilex Inc. (NASDAQ:PMCB) CEO Joshua Silverman acquired 40,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were purchased at an average price of $0.83 per share, with a total value of $33,200.00. Following the transaction, the chief executive officer owned 416,250 shares in the company, valued at $345,487.50. The trade was a 10.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Joshua Silverman also recently made the following trade(s):

• On Monday, January 5th, Joshua Silverman bought 30,000 shares of Nuvilex stock. The stock was purchased at an average price of $0.78 per share, with a total value of $23,400.00.

Nuvilex Stock Down 4.3%

Shares of NASDAQ:PMCB opened at $0.88 on Friday. Nuvilex Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $1.90. The firm’s 50-day simple moving average is $0.84 and its 200-day simple moving average is $0.94. The company has a market cap of $8.93 million, a price-to-earnings ratio of -0.63 and a beta of 0.04.

Nuvilex (NASDAQ:PMCB) last announced its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuvilex has an average rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.